Telix completes enrollment for first-line glioblastoma study
Go back to Telix completes enrollment for first-line glioblastoma study| TRANS-LUX CORPORATION (NASDAQ: TLX) | Delayed: 10.86 -0.04 (0.37%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.90 | 52 Week High | $2.18 | |||
| Open | $10.83 | 52 Week Low | $0.30 | |||
| Day High | $10.95 | P/E | N/A | |||
| Day Low | $10.78 | EPS | $-3.32 | |||
| Volume | 107,481 | |||||
